Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 1248

Next Previous
X
Search
Drug Profile

MK 1248

Alternative Names: MK1248

Latest Information Update: 22 Nov 2019

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 22 Nov 2019 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Monotherapy) in Australia (IV) (NCT02553499) (Merck pipeline, November 2019)
  • 04 Nov 2019 Merck terminates a phase I trial in Solid tumours (Late-stage disease, Monotherapy and in Combination therapy, Metastatic disease) in Australia (IV) due to programme prioritisation & not due to any safety concerns (NCT02553499)
  • 28 Dec 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Monotherapy) in Australia (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top